Figure 4

Changes of endoscopy and pathological features of patient2 and patient3 after them accepting celecoxib treatment. EUS, endoscopic ultrasonography. HE, hematoxylin eosin staining. AB-PAS, alcian blue-periodic acid stiff staining. P2, patient2. P3, patient3. Patient2 and patient3 were treated with celecoxib for 3 months. The effect of the treatment was shown by endoscopy (a,e,i,m) and endoscopic ultrasonography (b,f,j,n) as well as HE staining (c,g,k,o) and AB-PAS staining (d,h,l,p). The thickness of gastric mucosa declined after treatment (e,f,m,n). Consistently, patients showed inflammation, mucous glandular proliferation and intracellular mucus increase before treatment (c,d,k,l) and all these symptoms were reduced by treatment, but glandular proliferation still exist (g,h,o,p). Pathological diagnosis was provided by professional pathologist.